Although several anti-vascular endothelial growth factor (VEGF) agents have been largely employed for the treatment of various retinal diseases, other molecules with different therapeutic targets are being investigated. Among them, antiintegrin drugs have shown promising results for the treatment of ocular diseases. Risuteganib (ALG-1001, Luminate) is a novel anti-integrin drug formed by a synthetic arginyl-glycyl-aspartic (RGD) acid peptide which modulates the biological activities of several integrin isoforms. Results from phase II studies have outlined a promising clinical efficacy and tolerability profile for risuteganib in the treatment of diabetic macular edema and vitreous tractional macular syndrome. Moreover, ongoing trials are investigating its role for treating macular degeneration and retinal dystrophies. Further randomized, larger-scale trials will better characterize its potential clinical effectiveness for treating these vitreoretinal disorders.
- Age-related macular degeneration
- Diabetic macular edema
- Integrin inhibitors
ASJC Scopus subject areas
- Pharmacology (medical)